var data={"title":"Recombinant hemagglutinin influenza vaccine: Pediatric drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Recombinant hemagglutinin influenza vaccine: Pediatric drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/540360?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=recombinant-hemagglutinin-influenza-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Recombinant hemagglutinin influenza vaccine: Drug information&quot;</a> and <a href=\"topic.htm?path=recombinant-hemagglutinin-influenza-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Recombinant hemagglutinin influenza vaccine: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50338610\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is reporting a significant increase in influenza activity over recent weeks, with influenza A(H3N2) viruses predominating. Past A(H3N2) virus-predominant influenza seasons have been associated with more hospitalizations and deaths in persons 65 years of age and older, as well as in young children, compared to other age groups. Influenza vaccine effectiveness has also been generally lower against A (H3N2) viruses than against influenza A (H1N1) pdm09 or influenza B viruses. Last influenza season, vaccine effectiveness against circulating A (H3N2) viruses was estimated to be 32% in the US and is expected to be similar this season if the same A (H3N2) viruses continue to predominate. Influenza activity was high in the Southern Hemisphere in 2017 and preliminary data from Australia suggest overall vaccine effectiveness of 33% but only 10% against A (H3N2) viruses, making the use of antiviral medications for treatment of influenza, in addition to preventive vaccination, even more important.</p>\n        <p style=\"text-indent:0em;\">The CDC has also issued a health advisory stating that all hospitalized patients, patients with severe, complicated, or progressive illness (including outpatients), and all high-risk patients (including pediatric patients younger than 2 years; adults 65 years and older; patients with certain chronic illnesses or neurologic or neurodevelopmental conditions; immunosuppressed patients; women who are pregnant or postpartum (within 2 weeks of delivery); patients younger than 19 years of age receiving long term aspirin therapy; American Indians/Alaska Natives; patients with BMI of 40 or more; and residents of nursing homes or other chronic-care facilities) with suspected or confirmed influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral (eg, oseltamivir, peramivir, zanamivir). Adamantanes (eg, amantadine, rimantadine) are not currently recommended for treatment or prophylaxis of influenza A because of high levels of resistance. Antivirals for influenza work best when initiated within 48 hours of illness onset; however, clinical benefit has been observed even when treatment is initiated later in some patients.</p>\n        <p style=\"text-indent:0em;\">Further information is available at <a target=\"_blank\" href=\"https://emergency.cdc.gov/han/han00409.asp&amp;token=/XpciKoGXD/NBcI56myByIrj6XDzXmi2bFm6I7VYATsTAoPzpN4M+ut5dGKrD6OM&amp;TOPIC_ID=88815\" target=\"_blank\">https://emergency.cdc.gov/han/han00409.asp</a> and <a target=\"_blank\" href=\"https://www.cdc.gov/flu/weekly/summary.htm&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtzxb+vTZhOOrHrvoZzklFBp7r1xCTELF4KBDcLrJouICpPDwRTIgOkmOCDxEXvOQ==&amp;TOPIC_ID=88815\" target=\"_blank\">https://www.cdc.gov/flu/weekly/summary.htm</a>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza New Recommendations</span>\n      <span class=\"collapsible-date\">August 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is recommending that core requirements for influenza immunization remain the same for the 2017&ndash;2018 flu season. The Advisory Committee on Immunization Practices (ACIP) is also recommending that any licensed, recommended, and age-appropriate trivalent or quadrivalent inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV) be allowed for pregnant women. The previous recommendation specified use of IIV for pregnant women. ACIP reiterated that the quadrivalent live attenuated influenza nasal spray vaccine (LAIV4) should not be used in any setting during the upcoming flu season. Afluria (IIV3) is now indicated for people 5 years and older (previously 9 years and older). The influenza vaccine strains approved for the 2017&ndash;2018 season in the US are:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Trivalent vaccines:</p>\n            <ul>\n              <li>\n                <p style=\"text-indent:0em;\">A/Michigan/45/2015 (H1N1) pdm09&ndash;like virus (updated)</p></li>\n              <li>\n                <p style=\"text-indent:0em;\">A/Hong Kong/4801/2014 (H3N2)&ndash;like virus</p></li>\n              <li>\n                <p style=\"text-indent:0em;\">B/Brisbane/60/2008&ndash;like virus (Victoria lineage)</p></li></ul></li>\n          <li>\n            <p style=\"text-indent:0em;\">Quadrivalent vaccines:</p>\n            <ul>\n              <li>\n                <p style=\"text-indent:0em;\">The 3 trivalent vaccines, plus B/Phuket/3073/2013&ndash;like virus (Yamagata lineage)</p></li></ul></li></ul></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16226377\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Flublok;</li>\n      <li>Flublok Quadrivalent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16353579\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Recombinant</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16353585\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=recombinant-hemagglutinin-influenza-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Recombinant hemagglutinin influenza vaccine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available (if possible, by the end of October) and prior to onset of influenza activity in the community; however, vaccination should continue throughout the influenza season as long as vaccine is available (CDC/ACIP [Grohskopf 2017]). <b>Note:</b> According to ACIP, doses administered &le;4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Immunization:</b> Adolescents &ge;18 years and Adults: IM: 0.5 mL per dose as a single dose per season.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b> There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b> There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21989641\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flublok:  (0.5 mL) [no egg protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flublok:  (0.5 mL) [thimerosal free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flublok Quadrivalent: 0.5 mL (0.5 mL) [egg free]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16226380\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16353586\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). US law requires that the date of administration; the vaccine manufacturer; lot number of vaccine; the administering person's name, title, and address; and documentation of the vaccine information statement (VIS; date on VIS and date given to patient) be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For IM administration only. Shake gently prior to use; inspect for particulate matter and discoloration prior to administration; avoid use if visible particles are present in the solution after shaking. Administer IM in the deltoid muscle; do not inject into the gluteal region or areas where there may be a major nerve trunk. Jet injectors should not be used to administer inactivated influenza vaccines unless otherwise indicated in product labeling. Currently Afluria and Afluria Quadrivalent are the only influenza vaccines in the US that can be given by a jet-injector device.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16226405\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Do not freeze. Discard if frozen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16353580\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine (FDA approved in ages &ge;18 years)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine annual vaccination with seasonal influenza vaccine for all persons &ge;6 months who do not otherwise have contraindications to the vaccine. ACIP recommends use of any age- and risk factor-appropriate product. Persons &ge;18 years may receive vaccination with the recombinant influenza vaccine (RIV). In addition to RIV, other products are available for certain patient populations: Persons &ge;6 months of age may receive the trivalent inactivated influenza vaccine (IIV3) or the quadrivalent inactivated influenza vaccine (IIV4). Although live attenuated influenza vaccine (LAIV4) is FDA approved for healthy nonpregnant persons aged 2 to 49 years, the ACIP recommends LAIV4 not be used for any population for the 2017-18 season due to concerns regarding low effectiveness during the 2013-14 and 2015-16 seasons (CDC/ACIP [Grohskopf 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16226373\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Influenza virus vaccine may be confused with perflutren lipid microspheres</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Influenza virus vaccine may be confused with tetanus toxoid and tuberculin products. Medication errors have occurred when tuberculin skin tests (PPD) have been inadvertently administered instead of tetanus toxoid products and influenza virus vaccine. These products are refrigerated and often stored in close proximity to each other.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Influenza virus vaccine may be confused with insulin. Medication errors have occurred when insulin was inadvertently administered instead of influenza virus vaccine. These products are refrigerated and may be stored in close proximity to each other.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16226396\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at <a target=\"_blank\" href=\"https://vaers.hhs.gov/esub/index&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD+0my2cUJQ&amp;TOPIC_ID=88815\" target=\"_blank\">https://vaers.hhs.gov/esub/index</a>.</b>  In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Central nervous system: Chills, fatigue, headache (more common in older adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Local: Injection site reactions (includes redness, swelling and firmness), pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough, nasal congestion, nasopharyngitis, pharyngolaryngeal pain, rhinorrhea, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Hypersensitivity reaction, pleuropericarditis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16226391\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Severe allergic reaction (eg, anaphylaxis) to any component of the vaccine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16226392\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Guillain-Barr&eacute; syndrome: Use with caution in patients with history of Guillain-Barr&eacute; syndrome (GBS); patients with history of GBS have a greater likelihood of developing GBS than those without. As a precaution, the ACIP recommends that patients with a history of GBS and who are at low risk for severe influenza complications, and patients known to have experienced GBS within 6 weeks following previous vaccination should generally not be vaccinated (consider influenza antiviral chemoprophylaxis in these patients). The benefits of vaccination may outweigh the potential risks in persons with a history of GBS who are also at high risk for complications of influenza. Influenza infection itself may cause Guillain-Barr&eacute; syndrome (CDC/ACIP [Grohskopf 2017]). Recent studies of patients who received the trivalent inactivated influenza vaccine or the monovalent H1N1 influenza vaccine have shown the risk of GBS is lower with vaccination than with influenza infection (Baxter 2013; Greene 2013; Kwong 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroid]); may have a reduced response to vaccination. Inactivated vaccine (IIV or RIV) is preferred over live virus vaccine for household members, healthcare workers and others coming in close contact with severely-immunosuppressed persons requiring care in a protected environment (ACIP [Kroger 2017]; CDC/ACIP [Grohskopf 2016]). Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: In a clinical trial of infants and children 6 months through 3 years of age, a decreased response to Flublok was reported compared to currently licensed US influenza vaccine for this population, suggesting that it would not be effective in children &le;3 years; safety and efficacy in older pediatric patients have not been established; use has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flublok and Flublok Quadrivalent are influenza vaccines produced using continuous insect cell lines. They are recombinant hemagglutinin (rHA) vaccines and do not use the influenza virus or eggs during the production process. ACIP states they may be used in persons with an egg allergy of any severity if otherwise appropriate (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Adult Immunization Schedule (ACIP [Kim 2017]). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Previous season vaccines: Influenza vaccines from previous seasons must not be used (ACIP [Kroger 2017]; CDC/ACIP [Grohskopf 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16226387\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Information specific to the use of RIV in pregnancy is limited (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women are at an increased risk of complications from influenza infection. Influenza vaccination with any licensed, recommended, age-appropriate vaccine is recommended for all women who are or may become pregnant during the influenza season and who do not otherwise have contraindications to the vaccine (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women should observe the same precautions as nonpregnant women to reduce the risk of exposure to influenza and other respiratory infections (CDC/HHS 2017). When vaccine supply is limited, focus on delivering the vaccine should be given to women who are pregnant or will be pregnant during the flu season, as well as mothers of newborns and contacts or caregivers of children &lt;5 years of age (CDC/ACIP [Grohskopf 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women exposed to this vaccine during pregnancy may contact the Flublok pregnancy registry at 888-855-7871.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16353587\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to re-establish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16226406\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes immunity to seasonal influenza virus by inducing specific antibody production. Each year the formulation is standardized according to the US Public Health Service. Preparations from previous seasons must not be used. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22551078\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Most adults have antibody protection within 2 weeks of vaccination (CDC/ACIP [Grohskopf 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: When vaccine is antigenically similar to circulating virus &ge;6 to 8 months (CDC/ACIP [Grohskopf 2016]); response may be diminished in persons &ge;65 years and limited evidence suggests titers may decline significantly 6 months following vaccination in this population (CDC/ACIP [Grohskopf 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16353589\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Pharmacies will stock the formulations(s) standardized according to the USPHS requirements for the season. Influenza vaccines from previous seasons must not be used.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Seasonal quadrivalent influenza vaccines contain two subtype A strains and two subtype B strains; trivalent influenza vaccines contain two subtype A strains and one subtype B strain. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50454581\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Flublok Quadrivalent Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mL (0.5 mL): $54.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG committee opinion no. 468: influenza vaccination during pregnancy. <i>Obstet Gynecol</i>. 2010;116(4):1006-1007.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/20859176/pubmed\" target=\"_blank\" id=\"20859176\">20859176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barre syndrome with vaccinations. <i>Clin Infect Dis</i>. 2013;57(2):197-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/23580737/pubmed\" target=\"_blank\" id=\"23580737\">23580737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Pregnant Women &amp; Influenza (Flu). Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service. Availabe at <a href=\"http://www.cdc.gov/flu/protect/vaccine/pregnant.htm\" target=\"_blank\">http://www.cdc.gov/flu/protect/vaccine/pregnant.htm</a>. Updated August 30, 2017. Accessed September 5, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Pregnant women &amp; influenza (flu). Atlanta: U.S. Department of Health and Human Services, Public Health Service, December 15, 2010. Available at <a href=\"http://www.cdc.gov/flu/protect/vaccine/pregnant.htm\" target=\"_blank\">http://www.cdc.gov/flu/protect/vaccine/pregnant.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cox MM, Patriarca PA, and Treanor J, &quot;FluBlok, a Recombinant Hemagglutinin Influenza Vaccine,&quot; <i>Influenza Other Respi Viruses</i>, 2008, 2(6):211-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/19453397/pubmed\" target=\"_blank\" id=\"19453397\">19453397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flublok (influenza vaccine) [prescribing information]. Meriden, CT: Protein Sciences Corporation; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greene SK, Rett MD, Vellozzi C, et al. Guillain-Barr&eacute; syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009-2011. <i>PLoS One</i>. 2013;8(6):e67185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/23840621/pubmed\" target=\"_blank\" id=\"23840621\">23840621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. <i>MMWR Recomm Rep</i>. 2017;66(2):1-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/28841201/pubmed\" target=\"_blank\" id=\"28841201\">28841201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwong JC, Vasa PP, Campetelli MA, et al. Risk of Guillain-Barr&eacute; syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. <i>Lancet Infecti Dis</i>. 2013;13(9):769-776.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/23810252/pubmed\" target=\"_blank\" id=\"23810252\">23810252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McPherson CE, &quot;Development of a Novel Recombinant Influenza Vaccine In Insect Cells,&quot; <i>Biologicals</i>, 2008, 36(6):350-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/18804387/pubmed\" target=\"_blank\" id=\"18804387\">18804387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Center for Immunization and Respiratory Diseases (NCIRD). General recommendations on immunization&mdash;recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in <i>MMWR Recomm Rep</i>. 2011;60:993]. <i>MMWR Recomm Rep</i>. 2011;60(2):1-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/21293327/pubmed\" target=\"_blank\" id=\"21293327\">21293327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rasmussen SA, Jamieson DJ, and Bresee JS, &quot;Pandemic Influenza and Pregnant Women,&quot; <i>Emerg Infect Dis</i>, 2008, 14(1):95-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/18258087/pubmed\" target=\"_blank\" id=\"18258087\">18258087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treanor JJ, El Sahly H, King J, et al, &quot;Protective Efficacy of a Trivalent Recombinant Hemagglutinin Protein Vaccine (Flublok&reg;) Against Influenza in Healthy Adults: A Randomized, Placebo-Controlled Trial,&quot; <i>Vaccine</i>, 2011, 29(44):7733-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-hemagglutinin-influenza-vaccine-pediatric-drug-information/abstract-text/21835220/pubmed\" target=\"_blank\" id=\"21835220\">21835220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Food and Drug Administration, &ldquo;FDA Updated Communication on Use of Jet Injectors With Inactivated Influenza Vaccines&rdquo;, October 26, 2011. Available at <a href=\"http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm\" target=\"_blank\">http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm</a></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 88815 Version 84.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50338610\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16226377\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F16353579\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F16353585\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F21989641\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F16226380\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16353586\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F16226405\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F16353580\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16226373\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16226396\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16226391\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16226392\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16226387\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F16353587\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16226406\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F22551078\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F16353589\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F50454581\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/88815|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=recombinant-hemagglutinin-influenza-vaccine-drug-information\" class=\"drug drug_general\">Recombinant hemagglutinin influenza vaccine: Drug information</a></li><li><a href=\"topic.htm?path=recombinant-hemagglutinin-influenza-vaccine-patient-drug-information\" class=\"drug drug_patient\">Recombinant hemagglutinin influenza vaccine: Patient drug information \t</a></li></ul></div></div>","javascript":null}